Efficacy and safety of Dentoxol® in the prevention of radiation-induced oral mucositis in head and neck cancer patients (ESDOM): a randomized, multicenter, double-blind, placebo-controlled, phase II trial.
Rajesh V LallaSebastián SoléSergio BecerraClaudia CarvajalPiero BettoliHernán LetelierAlejandro SantiniLorena VargasAlexander CifuentesFrancisco LarsenNatalia JaraJorge OyarzúnRichard FeinnEva BustamanteBenjamín MartínezDavid RosenbergTomas GalvánPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
The use of Dentoxol 5 times/day is safe and resulted in significantly fewer time-points with severe OM and a delay in the onset of severe OM, compared with a control rinse. A phase III clinical trial is warranted to confirm efficacy and address the limitations of this study.